TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26391697
Drug: Preservative-free fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free fixed-dose combination (FDC) of tafluprost 0.0015% and timolol 0.5%
Study: 24524229
Drug: Full PopART
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full PopART combination HIV prevention package including annual home-based HIV testing, promotion of medical male circumcision for HIV-negative men, and offer of immediate ART for those testing HIV-positive
Study: 15837835
Drug: Carvedilol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5 or 25 mg orally for 2 months)
Study: 15837835
Drug: Hydrochlorothiazide (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (dosage not specified, orally for 2 months)
Study: 2288297
Drug: YN-72 30
Normalized name: 1-chloro-3-ethyl-1-penten-4-yn-3-ol
DrugBank: Ethchlorvynol (DB00189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: YN-72 30 mg/day
Study: 2288297
Drug: YN-72 150
Normalized name: 1-chloro-3-ethyl-1-penten-4-yn-3-ol
DrugBank: Ethchlorvynol (DB00189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: YN-72 150 mg/day
Study: 2288297
Drug: YN-72 300
Normalized name: 1-chloro-3-ethyl-1-penten-4-yn-3-ol
DrugBank: Ethchlorvynol (DB00189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: YN-72 300 mg/day
Study: 27752075
Drug: High-dose folinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folinic acid (2 mg kg-1 per day, maximum 50 mg per day; n=23)
Study: 24649525
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid monitoring with target < 2 mmol/L
Study: 22727138
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT; V.A.C.® Therapy; KCI USA, Inc.)
Study: 25972454
Drug: Armodafinil 150
Normalized name: armodafinil 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 150 mg/day
Study: 12466165
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate 0.2% twice daily
Study: 14507154
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment approaches for fixation of mandibular fractures
Study: 7875025
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Ondansetron 8 mg IV infusion before CDDP, followed by 8 mg tablets in the afternoon and before sleeping on the first day, then 3 tablets of 8 mg daily for the next 3 days.
Study: 7875025
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Ondansetron 8 mg IV infusion on the first day, followed by the same regimen as Group A.
Study: 2151197
Drug: Doxazosin 1
Normalized name: doxazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 1 mg to 16 mg once daily
Study: 2151197
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg to 100 mg once daily
Study: 29315129
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block with 30 mL of ropivacaine 0.5% with 1:400,000 epinephrine
Study: 29315129
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block with active drug and 100 μg of ITM
Study: 29315129
Drug: Sham adductor
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham adductor canal block with 30 mL of normal saline
Study: 22386051
Drug: Home-use nonablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-use nonablative fractional laser device (daily treatments during active phase, twice-weekly during maintenance phase)
Study: 22386051
Drug: Home-use nonablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-use nonablative fractional laser device (twice-weekly treatments during maintenance phase)
Study: 12942250
Drug: Clotrimazole (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (specific topical antifungal agent)
Study: 10397513
Drug: Initial periodontal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial periodontal therapy and gingival curettage
Study: 29145468
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral hygiene instructions only)
Study: 1387475
Drug: Amlodipine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (single dose)
Study: 25945764
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium fluoride (SF) 0.11%
Study: 12828139
Drug: Anesthetic gel
Normalized name: Topicaine 4% Topical Anesthetic Gel
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic gel (lidocaine 25 mg/g plus prilocaine 25 mg/g)
Study: 2547028
Drug: Cisplatin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (120 mg/m2)
Study: 2547028
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus etoposide (100 mg/m2 on days 1, 2, and 3)
Study: 192510
Drug: Practolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (100 mg, three times daily)
Study: 19328023
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU unfractionated heparin (UFH)
Study: 19328023
Drug: 2500 IU
Normalized name: Vitamin A/Vitamin D 2500 IU-270 IU Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2500 IU low molecular weight heparin (LMWH, dalteparin)
Study: 17366247
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to treatment (took >= 80% of pills)
Study: 15111980
Drug: Extensive biopsy
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extensive biopsy using intravenous conscious sedation (IVCS) (24 biopsies)
Study: 15111980
Drug: Standard biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard biopsy using intrarectal lidocaine gel (6-12 biopsies, mean 10.1)
Study: 11495824
Drug: Clodronate 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1,600 mg/d
Study: 8071036
Drug: Iopromide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide (300 mg I/mL)
Study: 31494176
Drug: Constipation treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constipation treatments (1 to 2 per day)
Study: 31333215
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injection (MDI)
Study: 28039653
Drug: Phrenic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phrenic nerve block (PNB) with 4 ml (30 mg) of 0.75% ropivacaine (group P, n = 28)
Study: 26068548
Drug: α-keto acids
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-keto acids (KAS) supplementation (0.2 g kg(‐1) body weight each day)
Study: 19803233
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy at Shenque (CV 8)
Study: 19803233
Drug: Routine ward
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine ward treatment of stroke (control group)
Study: 19358501
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy
Study: 17155937
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg orally 1 hour before surgery (group E)
Study: 17155937
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet orally 1 hour before surgery (group C)
Study: 15103536
Drug: Cognitive-behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural treatment programme (18 sessions)
Study: 10872648
Drug: Teverelix 5
Normalized name: Teverelix
DrugBank: Teverelix (DB05624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teverelix 5 mg
Study: 10872648
Drug: Teverelix 3
Normalized name: Teverelix
DrugBank: Teverelix (DB05624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teverelix 3 mg
Study: 10872648
Drug: Teverelix 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teverelix 0.5 mg
Study: 8237139
Drug: Mianserin (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (20-60 mg daily)
Study: 3925112
Drug: Phenoxymethyl penicillin
Normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethyl penicillin (250 mg qid) for 10 days
Study: 28521549
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost 0.1% lotion
Study: 28521549
Drug: Minoxidil 5%
Normalized name: MINOXIDIL 5% SOLN,TOP
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minoxidil 5% lotion
Study: 28521549
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate 0.1% solution
Study: 28521549
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of latanoprost lotion and betamethasone valerate solution
Study: 28521549
Drug: Vehicle lotion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle lotion (control group)
Study: 27010596
Drug: Acupuncture (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (weekly for 5 consecutive weeks)
Study: 27010596
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (physical therapy, analgesia, and/or antiinflammatory drugs)
Study: 22118560
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (dalteparin, 5000 IU weight-adjusted dosage) with aspirin 80 mg
Study: 22118560
Drug: Aspirin 80
Normalized name: aspirin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 80 mg alone
Study: 22118560
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin with aspirin
Study: 2488034
Drug: Topical deoxycytidine
Normalized name: deoxycytidine
DrugBank: 2'-Deoxycytidine (DB02594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical deoxycytidine 10(‐4) M
Study: 334230
Drug: Nomifensine (50-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (50-225 mg daily for 2-26 weeks)
Study: 334230
Drug: Placebo, imipramine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, imipramine, desipramine, viloxazine, nortriptyline, combination of amitriptyline and chlordiazepoxide, diazepam
Study: 30827001
Drug: NAC followed
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC followed by gastrectomy + adjuvant chemotherapy (Arm B)
Study: 30827001
Drug: Gastrectomy +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrectomy + adjuvant chemotherapy with S‐1 (Arm A)
Study: 19338147
Drug: Xiaoliu Baofei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoliu Baofei Pill (XBP) plus chemotherapy
Study: 15664791
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone replacement therapy
Study: 11202817
Drug: Iontophoretically administered
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoretically administered lidocaine (anesthetic)
Study: 9276197
Drug: Bromocriptine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine monotherapy (11 patients)
Study: 9276197
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with bromocriptine and levodopa (35 patients)
Study: 8351163
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (0.5 mg) + Sublingual nifedipine (10 mg)
Study: 8351163
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (0.5 mg)
Study: 3032470
Drug: CAV1 (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV1 (cyclophosphamide 600 mg m‐2 i.v., adriamycin 50 mg m‐2 i.v., etoposide 500 mg m‐2 p.o. on day 3)
Study: 3032470
Drug: CAV5 (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV5 (cyclophosphamide and adriamycin as for CAV1, etoposide 500 mg m‐2 given in divided dose over days 3‐7)
Study: 26142345
Drug: Combination nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination nicotine replacement therapy (cNRT)
Study: 29389142
Drug: Incentive condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive condition participants received incentives for attending pre‐ and postbirth treatment contacts: $25 for each of 6 prebirth provider visits, $25-40 for each of 4 postbirth home visits, $20 for each of 5 postbirth counseling calls, and $40 for biochemically verified abstinence at Week 1 and 6-month visits.
Study: 21665048
Drug: New micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: New micronized powder formulation of artemisinin (160 or 500 mg)
Study: 21665048
Drug: Previous standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous standard Vietnamese formulation of artemisinin
Study: 18280375
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gel applied during the first postoperative week
Study: 17065884
Drug: Protective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective ventilation strategy (tidal volume of 9 ml/kg during two-lung ventilation, reduced to 5 ml/kg during one-lung ventilation; positive end-expiratory pressure 5 cm H2O throughout the operative time)
Study: 17065884
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation strategy (tidal volume of 9 ml/kg during two-lung and one-lung ventilation; no positive end-expiratory pressure)
Study: 10357295
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V potassium, 250 mg 3 times daily (n = 239)
Study: 10357295
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V potassium, 500 mg 2 times daily (n = 239)
Study: 1920391
Drug: Slow-release carbamazepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release carbamazepine (SR) preparation divided into two daily doses
Study: 1920391
Drug: Conventional carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional carbamazepine (C) preparation divided into three daily doses
Study: 7038182
Drug: 10% trolamine
Normalized name: TROLAMINE SALICYLATE 10 g in 100 g TOPICAL CREAM [Hempvana Maximum Strength Pain Relief Cream 10% Trolamine Salicylate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% trolamine salicylate cream
Study: 31047804
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (5·4 mg/kg or 6·4 mg/kg administered intravenously once every 3 weeks)
Study: 29052025
Drug: Ultra-low-dose (ULD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose (ULD) technique for CTCA
Study: 24382118
Drug: Ultra-high molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultra-high molecular weight polyethylene (UHMWPE) implant manufactured by CAM milling
Study: 16424586
Drug: Correction method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correction method for segmental dose errors
Study: 12198327
Drug: AIIRA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIIRA with no >L-NMMA
Study: 12198327
Drug: >L-NMMA co-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: >L-NMMA co-infusion
Study: 30890382
Drug: 1-week 4-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week 4-site ID regimen with purified Vero cell rabies vaccine (PVRV; Verorab®) without rabies immunoglobulin (RIG) (G1)
Study: 30347561
Drug: Medication of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication of 1 day prior to surgery (30 eyes)
Study: 30347561
Drug: Medication of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication of 3 days prior to surgery (30 eyes)
Study: 27501409
Drug: Prototype device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype device for drug administration (scanning required before injection)
Study: 22689690
Drug: pegylated IFNα2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated IFNα2a weekly for 48 weeks
Study: 19910118
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention (including Omnibus cognitive-behavioral therapy, relaxation therapy, and biofeedback)
Study: 19910118
Drug: Self-administered interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered interventions
Study: 19829284
Drug: Psychological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapies
Study: 19170462
Drug: Integrative behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative behavioral couple therapy
Study: 19170462
Drug: Traditional behavioral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional behavioral couple therapy
Study: 6515368
Drug: salbutamol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol 0.2 mg
Study: 8584530
Drug: fenoterol 0.2
Normalized name: fenoterol 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol 0.2 mg
Study: 8584530
Drug: salmeterol 0.05
Normalized name: salmeterol 0.05 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol 0.05 mg
Study: 2245947
Drug: Lactate gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate gel (5 ml, pH 3.8) inserted into the vagina daily for 7 consecutive days, followed by prophylactic treatment 3 days monthly for 6 months
Study: 2245947
Drug: Lactate gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate gel
Study: 17531279
Drug: Ivermectin low
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin low dose (25 microg/kg)
Study: 17531279
Drug: Ivermectin standard
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin standard dose (150 microg/kg)
Study: 17531279
Drug: Ivermectin low
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin low dose (25 microg/kg) with second dose after 15 days
Study: 9643622
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution containing 80 mg sotalol and 20 mg cisapride
Study: 9643622
Drug: Sublingual tablet
Normalized name: Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet of 80 mg sotalol
Study: 7895388
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 micrograms twice a day)
Study: 7895388
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) (200 micrograms twice a day)
Study: 23905373
Drug: Buyang Huanwu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buyang Huanwu Decoction (BHD) combined with Aspirin (ASP)
Study: 23905373
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and Aspirin (ASP)
Study: 9360513
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose step-up regimen
Study: 2981292
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with co-trimoxazole prophylaxis
Study: 2981292
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy without co-trimoxazole prophylaxis
Study: 26166531
Drug: General knowledge
Approvals — FDA: no, EMA: no, PMDA: no
Description: General knowledge of routine treatment and care (Control)
Study: 8922243
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy and RT
Study: 3215626
Drug: 2.5 MU
Normalized name: benzocaine/cetylpyridinium chl 10-2.5 MUCOUS MEM TROCHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 MU rIFN-alpha/m2 body surface 3 times weekly i.m. during 6 months
Study: 3215626
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU rIFN-alpha/m2 body surface 3 times weekly i.m. during 6 months
Study: 3215626
Drug: 10 MU
Normalized name: saliva substitute comb no.10 MUCOUS MEM POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 MU rIFN-alpha/m2 body surface 3 times weekly i.m. during 6 months
Study: 29661382
Drug: Manual Infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual Infusion
Study: 28895933
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein intake (HP) group (n = 11) received a dietary plan with 1.2 g·kg‐1·day‐1 of protein
Study: 28895933
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein (NP) group (n = 12) ingested 0.8 g·kg‐1·day‐1 of protein (RDA recommendation)